APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

<p>Abstract</p> <p>Background</p> <p>5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma. Low toxicity and convenience of administration facilitate use, however clinical resist...

Full description

Bibliographic Details
Main Authors: McKinlay Aileen, Aly Emad, Binnie Norman, Loudon Malcolm, O'Kelly Terrence, MacDonald Graham, Murray Graeme I, Samuel Leslie M, Petty Russell D, Wang Weiguang, Gilbert Fiona, Semple Scot, Collie-Duguid Elaina SR
Format: Article
Language:English
Published: BMC 2009-12-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/9/434

Internet

http://www.biomedcentral.com/1471-2407/9/434

Similar Items